The Exchange has sought clarification from Natco Pharma Limited with respect to recent news item captioned Eris Lifesciences inks deal with Natco Pharma for weight-loss drug semaglutide.. The response from the Company is attached.
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.7 pts more than Nifty Smallcap 250 and 3.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Natco Pharma responded to NSE's query about a news item claiming Eris Lifesciences inked a deal with Natco for the weight-loss drug semaglutide. The company confirmed it received CDSCO approval for semaglutide in India on February 14, 2026, and is working with multiple marketing partners to launch the product in March 2026. Natco described the Eris Lifesciences partnership as part of ordinary course of business with no material impact on operations. The company also confirmed there is no undisclosed information that could explain unusual trading activity and no material financial impact from the news article.
The company is explicitly downplaying the deal's significance, stating it has no material impact on operations or finances. This may temper investor enthusiasm and could ease any concerns about unusual stock price movement tied to the news.